Fulcrum therapeutics reports qtrly loss per share $0.97

Fulcrum therapeutics reports third quarter 2019 financial results and recent business highlights.fulcrum therapeutics inc qtrly loss per share $0.97.fulcrum therapeutics - as of sept 30, 2019, cash and cash equivalents were $101.6 million, as compared to $72.8 million as of dec 31, 2018.fulcrum therapeutics - sees existing cash,cash equivalents, to be sufficient to enable to fund operating expenses, capex requirements into q3 2021.
FULC Ratings Summary
FULC Quant Ranking